HIV Type-1 Drug Resistance in Treatment-Naive Patients Monitored Using Minority Species Assays: A Systematic Review and Meta-Analysis

Abstract

Background

The detection of mutations associated with drug resistance in HIV type-1 might be increased by applying minority species assays capable of identifying low frequency mutations in comparison with the use of population sequencing alone. Because minority species assays are mutation-specific, the benefit of this approach differs depending on the mutation being detected.

Methods

We performed a systematic review of published data reporting detection of genotypic drug resistance using allele-specific (AS)-PCR minority assays and by standard DNA sequencing in drug-naive populations. We calculated the fold increase of mutation detection for each study and pooled these via meta-analysis, displaying results using Forest plots.

Results

Our studies revealed an increase in detection of 1.9-fold (95% confidence interval [CI] 1.3–2.7; P<0.0005) for K103N, 4.4-fold (95% CI 1.2–16.6; P=0.026) for Y181C, 4.8-fold (95% CI 1.5–15.1; P=0.008) for L90M and 8.7-fold (95% CI 4.0–18.6; P<0.0005) for M184V. We found no relationship between AS-PCR assay sensitivity and frequency of additional mutation detection.

Conclusions

Additional detection of drug resistance mutations using AS-PCR minority mutation assays vary significantly depending on the mutation examined; however, the most marked increase in detection of resistance mutations was observed for M184V, a mutation seldom detected by standard techniques in drug-naive patients. We suggest that the presence of drug resistance mutations can be more accurately estimated using a combination of AS-PCR and standard genotyping.

References

Palella

F.J.

Jr. , Delaney

K.M.

, Moorman

A.C.

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853–860.

Gazzard

B.G.

British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008; 9: 563–608.

Pao

, Andrady

, Clarke

Long-term persistence of primary genotypic resistance after HIV-1 seroconversion. J Acquir Immune Defic Syndr 2004; 37: 1570–1573.

Palmer

, Kearney

, Maldarelli

Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol 2005; 43: 406–413.

, Chiarella

, Simen

B.B.

Low-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use. PLoS ONE 2009; 4: e6079.

Simen

B.B.

, Simons

J.F.

, Hullsiek

K.H.

Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J Infect Dis 2009; 199: 693–701.

Cai

, Chen

, Hicks

C.B.

Detection of minor drug-resistant populations by parallel allele-specific sequencing. Nat Methods 2007; 4: 123–125.

Lalonde

M.S.

, Troyer

R.M.

, Syed

A.R.

Sensitive oligonucleotide ligation assay for low-level detection of nevirapine resistance mutations in human immunodeficiency virus type 1 quasispecies. J Clin Microbiol 2007; 45: 2604–2615.

Punia

, Cane

, Teo

C.G.

Quantitation of hepatitis B lamivudine resistant mutants by real-time amplification refractory mutation system PCR. J Hepatol 2004; 40: 986–992.

10.

DerSimonian

, Laird

Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177–188.

11.

Higgins

J.P.

, Thompson

S.G.

, Deeks

J.J.

Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557–560.

12.

Paredes

, Lalama

C.M.

, Ribaudo

H.J.

Pre-exisiting minority drug resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J Infect Dis 2010; 201: 662–671.

13.

Cane

P.A.

Stability of transmitted drug-resistance HIV-1 species. Curr Opin Infect Dis 2005; 18: 537–542.

14.

Cong

M.E.

, Heneine

, Garcia-Lerma

J.G.

The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions. J Virol 2007; 81: 3037–3041.

15.

Buckton

A.J.

, Prabhu

, Motamed

Increased detection of the HIV-1 reverse transcriptase M184V mutation using mutation-specific minority assays in a UK surveillance study suggests evidence of unrecognized transmitted drug resistance. HIV Med 2010. doi 10.1111/j.1468-1293.2010.00882.x.

16.

Coffin

J.M.

HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995; 267: 483–489.

17.

Bakhanashvili

, Hizi

Fidelity of the RNA-dependent DNA synthesis exhibited by the reverse transcriptases of human immunodeficiency virus types 1 and 2 and of murine leukemia virus: mispair extension frequencies. Biochemistry 1992; 31: 9393–9398.

18.

Johnson

J.A.

, Li

J.F.

, Morris

Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis 2005; 192: 16–23.

19.

Metzner

K.J.

, Allers

, Rauch

Rapid selection of drug-resistant HIV-1 during the first months of suppressive ART in treatment-naive patients. AIDS 2007; 21: 703–711.

20.

Pillay

, Ledwaba

, Hunt

Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004. Antivir Ther 2008; 13: 101–107.

21.

Johnson

J.A.

, Li

J.F.

, Wei

Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med 2008; 5: e158.

22.

Metzner

K.J.

, Rauch

, von Wyl

Efficient suppression of minority quasispecies of drug-resistant viruses present at primary HIV-1 infection by boosted PI-containing ART. 16th Conference on Retroviruses and Opportunistic Infections. 8–11 February 2009, Montreal, QC, Canada. Abstract 649.

23.

Toni

T.A.

, Asahchop

E.L.

, Moisi

Detection of human immunodeficiency virus (HIV) type 1 M184V and K103N minority variants in patients with primary HIV infection. Antimicrob Agents Chemother 2009; 53: 1670–1672.

24.

Hauser

, Mugenyi

, Kabasinguzi

Detection and quantification of minor human immunodeficiency virus type 1 variants harburing K103N and Y181C resistance mutations in subtype A and D isolates by allele-specific real-time PCR. Antimicrob Agents Chemother 2009; 53: 2965–2973.

25.

Coovadia

, Hunt

, Abrams

E.J.

Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy. Clin Infect Dis 2009; 48: 462–472.

26.

Metzner

K.J.

, Giulieri

S.G.

, Knoepfel

S.A.

Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients. Clin Infect Dis 2009; 48: 239–247.

27.

Vignoles

, Barboni

, Agosti

M.R.

Evaluation of minority populations of HIV type-1 with K103N and M184V resistance mutations among children in Argentina. Antivir Ther 2009; 14: 1175–1181.

28.

Metzner

K.J.

, Rauch

, Walter

Detection of minor populations of drug-resistant HIV-1 in acute seroconverters. AIDS 2005; 19: 1819–1825.

29.

Giulieri

S.G.

, Knoepfel

S.A.

, Rauch

Minority quasispecies of drug-resistant HIV-1 leading to early therapy failure in treatment-naive and adherent patients. Antivir Ther 2008; 13 Suppl 3: A116.

30.

Bestetti

, Soria

, Galli

Dynamics of the M184V mutation by allele-specific PCR (AS-PCR) in patients receiving lamivudine or entricitabine monotherapy or undergoing treatment interruption (TI). Antivir Ther 2008; 13 Suppl 3: A122.

31.

Van Laethem

, De Munter

, Schrooten

No Response to first-line tenofovir+lamivudine+efavirenz despite optimization according to baseline resistance testing: impact of resistant minority variants on efficacy of low genetic barrier drugs. J Clin Virol 2007; 39: 43–47.

32.

Kapoor

, Shapiro

, Shafer

Multiple independent origins of a protease inhibitor resistance mutation in salvage therapy patients. Retrovirology 2008; 5: 7.

33.

Dykes

, Najjar

, Bosch

Detection of minority drug-resistant variants of HIV-1 during virologic failure of lamivudine, indinavir and zidovudine or stavudine in ACTG 320. 16th Conference on Retroviruses and Opportunistic Infections. 8–11 February 2009, Montreal, QC, Canada. Abstract 607.

34.

Palmer

, Boltz

, Martinson

Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. Proc Natl Acad Sci U S A 2006; 103: 7094–7099.

35.

Perez

, Vignoles

, Laufer

Low rate of emergence of nevirapine and lamivudine resistance after post-partum interruption of a triple-drug regimen. Antivir Ther 2008; 13: 135–139.

36.

Peuchant

, Thiebaut

, Capdepont

Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy. AIDS 2008; 22: 1417–1423.

37.

Metzner

K.J.

, Rauch

, von Wyl

Prevalence of minority quasispecies of drug resistant HIV-1 in patients with primary HIV-1 infection in Zurich in the years 2002–2006. Antivir Ther 2007; 12 Suppl 1: S47.